Formaldehyde-Inactivated Whole-Virus Vaccine Protects a Murine Model of Enterovirus 71 Encephalomyelitis against Disease
Key result
A formaldehyde-inactivated whole-virus vaccine derived from a mouse-adapted EV71 virus protected mice from encephalomyelitis disease at 14 days of age after two immunizations.
Why the study?
Does a formaldehyde-inactivated whole-virus vaccine protect against disease in a murine model of EV71 encephalomyelitis?
Population
Murine model of Enterovirus 71 encephalomyelitis
Design
Preclinical
Follow-up
14 days of age
Authors
Discussion
Loading...
Member takes
Implication
Provides basis for EV71 vaccine development; leaves open human clinical translation.
Structured PICO
Does a formaldehyde-inactivated whole-virus vaccine protect against disease in a murine model of EV71 encephalomyelitis?
P
Population
Mice immunized at 1 and 7 days of age and adult mice evaluated for protection against EV71 encephalomyelitis.
I
Intervention
Formaldehyde-inactivated whole-virus vaccines derived from EV71 clinical isolates and a mouse-adapted virus (MAV), given as two immunizations at 1 and 7 days of age
O
Outcome
Protection from disease at 14 days of agehard clinical
A formaldehyde-inactivated whole-virus vaccine protects against EV71 encephalomyelitis in a mouse model, providing a potential basis for vaccine development.
Cite This Study
Ong et al. (2009) studied Enterovirus 71 encephalomyelitis. Formaldehyde-inactivated whole-virus vaccine (MAV) was evaluated on Protection from disease at 14 days of age. A formaldehyde-inactivated whole-virus vaccine derived from a mouse-adapted EV71 virus protected mice from encephalomyelitis disease at 14 days of age after two immunizations.